Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -49.78% is in line with its 5-year average of -47.51%, around the middle of its 5-year range (-77.80%–-17.77%).
As of the fiscal period ended Tuesday, June 30, 2026. 4.52% above its 12-month average of -52.14%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -49.78%.
RETURN ON INVESTED CAPITAL (ROIC)
-49.78%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-52.14%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-53.11%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-47.51%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+4.52%
CURRENT VS 3Y AVG
+6.26%
CURRENT VS 5Y AVG
-4.77%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
8.40%
median of 98 covered companies
CURRENT VS SECTOR MEDIAN
-692.64%
vs the sector median at left
Recursion Pharmaceuticals, Inc.
Market Cap
$2.13B
Return on Invested Capital (ROIC)
-49.78%
TTM Avg
-52.14%
3Y Avg
-53.11%
5Y Avg
-47.51%
Market Cap
$2.49B
Return on Invested Capital (ROIC)
-28.96%
TTM Avg
-36.25%
3Y Avg
-29.21%
5Y Avg
-30.95%
Market Cap
$1.74B
Return on Invested Capital (ROIC)
10.03%
TTM Avg
-6.49%
3Y Avg
-7.14%
5Y Avg
-3.83%
Market Cap
$1.71B
Return on Invested Capital (ROIC)
-54.45%
TTM Avg
-54.60%
3Y Avg
-46.39%
5Y Avg
-38.46%
Market Cap
$2.72B
Return on Invested Capital (ROIC)
5.87%
TTM Avg
7.96%
3Y Avg
-0.22%
5Y Avg
-9.17%
Market Cap
$1.01B
Return on Invested Capital (ROIC)
-7.32%
TTM Avg
-21.18%
3Y Avg
-91.27%
5Y Avg
-61.58%
Market Cap
$470.35M
Return on Invested Capital (ROIC)
-5.29%
TTM Avg
-5.58%
3Y Avg
-6.88%
5Y Avg
-5.95%
Market Cap
$459.30M
Return on Invested Capital (ROIC)
8.75%
TTM Avg
20.32%
3Y Avg
26.86%
5Y Avg
29.17%
Market Cap
$389.98M
Return on Invested Capital (ROIC)
-25.26%
TTM Avg
-29.12%
3Y Avg
-26.65%
5Y Avg
-26.65%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Recursion Pharmaceuticals, Inc. (RXRX) | $2.13B | -49.78% | -52.14% | -53.11% | -47.51% |
| Beam Therapeutics Inc. (BEAM)vs › | $2.49B | -28.96% | -36.25% | -29.21% | -30.95% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.74B | 10.03% | -6.49% | -7.14% | -3.83% |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.71B | -54.45% | -54.60% | -46.39% | -38.46% |
| TransMedics Group, Inc. (TMDX)vs › | $2.72B | 5.87% | 7.96% | -0.22% | -9.17% |
| Teladoc Health, Inc. (TDOC)vs › | $1.01B | -7.32% | -21.18% | -91.27% | -61.58% |
| NeoGenomics, Inc. (NEO)vs › | $470.35M | -5.29% | -5.58% | -6.88% | -5.95% |
| NRC Health (NRC)vs › | $459.30M | 8.75% | 20.32% | 26.86% | 29.17% |
| Shoulder Innovations, Inc. (SI)vs › | $389.98M | -25.26% | -29.12% | -26.65% | -26.65% |
| PDS Biotechnology Corporation (PDSB)vs › | $41.24M | -3699.99% | -104.88% | -89.50% | -74.29% |
ROIC
-49.8%
ROE
-56.7%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -49.78% |
| 2026-03-31 | -48.01% |
| 2025-12-31 | -48.53% |
| 2025-09-30 | -57.73% |
| 2025-06-30 | -56.64% |
| 2025-03-31 | -48.99% |
| 2024-12-31 | -37.73% |
| 2024-09-30 | -62.98% |
| 2024-06-30 | -56.65% |
| 2024-03-31 | -77.80% |
| 2023-12-31 | -62.45% |
| 2023-09-30 | -58.08% |
| 2023-06-30 | -49.72% |
| 2023-03-31 | -48.45% |
| 2022-12-31 | -40.88% |
| 2022-09-30 | -47.24% |
| 2022-06-30 | -40.55% |
| 2022-03-31 | -32.11% |
| 2021-12-31 | -32.42% |
| 2021-09-30 | -23.29% |
| 2021-06-30 | -17.77% |
| 2021-03-31 | -39.14% |
| 2020-12-31 | -30.60% |
